Xilio Therapeutics

XLO55

Penny Stock

$1.00arrow_drop_up0.24%$0.00

Penny Stock

XLO55

$1.00

arrow_drop_up0.24%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.95
Prev. Close	$0.99
EPS	-1.98
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$47.47M
PE Ratio	-

	LOW	HIGH
Day Range	0.95	1.03
52 Week Range	0.49	2.89

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.98

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Xilio Therapeutics (XLO)

Xilio Therapeutics, Inc. (XLO) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer treatment. The company's mission is to leverage its proprietary technology platform, which combines tumor cell-selective potent immune activation with localized therapeutic payload delivery, to revolutionize cancer treatment. Xilio Therapeutics is headquartered in Boston, Massachusetts and was founded in 2016.

Xilio Therapeutics' lead product candidate, XTX101, is a novel immunotherapy designed to activate a patient's immune system to target and destroy cancer cells. XTX101 is currently being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. The company's approach is based on the concept of using a tumor-selective immunostimulant to activate immune cells specifically at the tumor site, while sparing normal tissues from immune activation.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
Headquarters: Waltham
Employees: 84
Exchange: NASDAQ

Keep an eye on Xilio Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the 52-week high and low for Xilio Therapeutics (XLO)?

For Xilio Therapeutics (XLO), the 52-week high is $2.89, which is 189.4% from the current price. The 52-week low is $0.49, the current price is 104.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is Xilio Therapeutics's (XLO) price per share?

The current price per share for Xilio Therapeutics (XLO) is $1. The stock has seen a price change of $0 recently, indicating a 0.24% change. This reflects the stock's recent market performance and investor sentiment.

help

Is Xilio Therapeutics (XLO) a growth stock?

Xilio Therapeutics (XLO) has shown an average price growth of -3.55% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xilio Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Xilio Therapeutics (XLO) stock price performance year to date (YTD)?

As of the latest data, Xilio Therapeutics (XLO) has a year-to-date price change of 73.91%. Over the past month, the stock has experienced a price change of 28.87%. Over the last three months, the change has been 25.8%. Over the past six months, the figure is -10.71%.

help

Is Xilio Therapeutics (XLO) a profitable company?

Xilio Therapeutics (XLO) has a net income of -$76.4K, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -622.57% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$79.13M. Furthermore, the EBITDA is -$64.91M.

help

What is the market capitalization of Xilio Therapeutics (XLO)?

Xilio Therapeutics (XLO) has a market capitalization of $44.6M. The average daily trading volume is 1.02, indicating the stock's liquidity and investor engagement.

News

ADVANCED SOLID TUMORS

SITC

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

DIRECTORS AND OFFICERS

Jun 13, 2024

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

EARNINGS RELEASES AND OPERATING RESULTS

May 14, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 26, 2024

Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

Apr 16, 2024

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

NEWS

PENNY STOCKS